Key points are not available for this paper at this time.
Real world data are advocated as an alternative approach to RCTs for closing knowledge gaps on drugs, but Beate Wieseler and colleagues argue that this approach is the wrong remedy for current challenges in drug development
Wieseler et al. (Thu,) studied this question.